Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC7401 in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT07444086Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
01
Overview
A Phase 3 trial of rbd7022 in hypercholesterolemia, mixed dyslipidemia, sponsored by Qilu Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07444086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444086.